

Susan J. Borghoff, M.S.P.H., Ph.D., DABT

VICE PRESIDENT, 21CT
PRINCIPAL SCIENTIST

CONTACT INFORMATION

ToxStrategies, A BlueRidge Life Sciences Company
600 Park Offices Drive, Suite 300
PO Box 13965
Durham, NC 27709
Office (919) 912-5583
Cell (919) 491-8260
sborghoff@toxstrategies.com

PROFESSIONAL PROFILE

Dr. Susan Borghoff is based in Research Triangle Park, NC. She is a board-certified toxicologist with over 35 years of experience designing and managing diverse research programs and regulator-driven *in vitro* and *in vivo* toxicology studies for commercial and federal clients. Her work has also included scientific and technical oversight, data analysis and interpretation, and preparation of both Final GLP Study Reports for regulatory submission and peer-reviewed scientific manuscripts. Dr. Borghoff has directed scientific research to support dose-response and hazard identification for incorporation into human health risk assessments.

Dr. Borghoff is a recognized expert on mechanisms by which agents cause toxicity, modulate endocrine pathways, and cause cancer in rodents, and the relevance of these responses for assessing human risk. Most recently, she has been involved in evaluating mechanistic data combined with experimental cancer animal studies to assess the potential of selected sweeteners to cause cancer in humans. Her research also has focused on understanding the metabolism and pharmacokinetics of agents using physiologically based pharmacokinetic (PBPK) models for extrapolation of risk to humans. She has been involved with critical reviews of toxicity and carcinogenicity studies, advising on specific study designs to fill data gaps for understanding modes/mechanisms of action, and as an Expert Panel member for scientific oversight of industry-sponsored toxicity and carcinogenicity testing programs. Dr. Borghoff's experience also includes implementing a program to conduct GLP regulatory studies associated with the United States Environmental Protection Agency (EPA)-mandated Endocrine Disruption Screening Program (EDSP) and co-chairing a workshop titled, "Lessons Learned, Challenges, and Opportunities: The US Endocrine Disruptor Screening Program," held in Research Triangle Park in 2013, to assess this program.

Dr. Borghoff has served as a reviewer on a number of panels and working groups for international organizations, including EPA, National Cancer Institute, International Programme on Chemical Safety (IPCS), and European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC). She also served on three Monograph Working Groups (Vol. 73, 77, and 82) of the International Agency for Cancer Research (IARC), in addition to acting as Observer for Monograph Vol.115, 134, and for the advisory group meeting to recommend priorities (March 2019). She has been a reviewer for various grants through the National Institutes of Health (NIH), the National Institute of Environmental Health Sciences (NIEHS), and EPA.

Dr. Borghoff received the Frank R. Blood Award in 1994 for the best paper of the year published in a Society of Toxicology (SOT) research journal, and an SOT Risk Assessment Specialty Section Award in 2000. She is a member of SOT's North Carolina Chapter, and at the national level, has served on SOT Council, as well as various committees (e.g., Program, Awards, Education). Dr. Borghoff was a member of SOT's TSCA Reform Task Force and was the Audit Committee Co-Chair. She has also served as an Associate Editor for *Toxicological Sciences*, along with other editorial positions for several scientific journals, including the editorial board of the *International Journal of Toxicology*.

Dr. Borghoff received her Ph.D. and MSPH in Environmental Sciences and Engineering from the University of North Carolina, and a B.S. in Chemistry from East Stroudsburg University in Pennsylvania. Dr. Borghoff became a Diplomate of the American Board of Toxicology in 1994.

EDUCATION AND DEGREES EARNED

Ph.D., Environmental Sciences and Engineering, University of North Carolina

M.S.P.H., Environmental Sciences and Engineering, University of North Carolina

B.S., Chemistry (*magna cum laude*), East Stroudsburg University, East Stroudsburg, PA

CERTIFICATIONS

Diplomate, American Board of Toxicology (Recertification: 1999, 2004, 2009, 2014, 2020, 2025)

PROFESSIONAL AFFILIATIONS

1984–Present	North Carolina Chapter of the Society of Toxicology
1986–Present	Society of Toxicology (Full Member over 35 yrs)
2019–Present	American Society for Cellular and Computational Toxicology
2015–2017	Audit Committee; Co-chair 2015, Chair 2016 (appointed)
2013–2016	TSCA Reform Task Force (appointed)
2009–2011	Councilor (elected)
2005–2008	Education Committee (elected)
2002–2004	Awards Committee (elected)
1999–2004	Program Committee (appointed)
2002–2004	Secretary/Treasurer of BMSS
2007–Present	American College of Toxicology

2013–Present	SETAC (Society of Environmental Toxicology and Chemistry)
2018–Present	Toxicology Forum
1992–2010	International Society for the Study of Xenobiotics
2003–2010	RTP Drug Metabolism Discussion Group (Executive Board)

AWARDS AND HONORS

2017	Recognized by the Biological Modeling Specialty Section of the Society of Toxicology for publication of one of the top nine modeling papers in 2017: Borghoff SJ, Ring C, Banton M, Leavens TL. 2016. Physiologically based pharmacokinetic model for ethyl tertiary-butyl ether and tertiary-butyl alcohol in rats: Contribution of binding to α 2u-globulin in male rats and high-exposure nonlinear kinetics to toxicity and cancer outcomes. <i>J Appl Toxicol</i> 37(5):621–640, doi 10.1002/jat.3412.
2000	Society of Toxicology Risk Assessment Specialty Section Award for outstanding presentation in risk assessment: “A physiologically-based pharmacokinetic model for methyl tert-butyl ether in humans” (Student Award—Amy Collins Licata).
1994	Frank R. Blood Award for Outstanding Paper published in SOT journal: Borghoff SJ, Lagarde WH. 1993. Assessment of binding of 2,4,4-trimethyl-2-pentanol to low-molecular weight proteins isolated from kidneys of male rats and humans. <i>Toxicol Appl Pharmacol</i> 119:228–235.
1987	National Kidney Foundation Research Fellowship, North Carolina Society of Toxicology—Study Travel Award
1986	National Society of Toxicology—Study Travel Award
1982–1987	Public Health Traineeship—University of North Carolina

EDITORIAL AND REVIEWER ACTIVITIES

Associate Editor

Toxicological Sciences (2004–2008)—focus on reviews associated with PBPK models, pharmacokinetics, endocrine disruptors, kidney toxicity, and cancer

Editorial Board

International Journal of Toxicology (2014–2024)
Chemico-Biological Interactions (2000–2008)
Toxicological Sciences (2000–2003)
Toxicology Letters (1995–2000)

Ad Hoc Reviewer

Regulatory Toxicology and Pharmacology
Environmental Health Perspectives
Toxicology and Applied Physiology
CRC Reviews in Toxicology
Journal of Toxicology and Environmental Health
Life Sciences Reviews
Toxicological Pathology
Risk Analysis

NATIONAL & INTERNATIONAL ADVISORY COMMITTEES, SCIENTIFIC MEETING ORGANIZER, AND INVITED SPEAKER

Chair and Speaker, Informational session: Five decades of evaluating the safety of aspartame consumption: Has anything changed? Society of Toxicology, March 2024.

International Agency for Research on Cancer (IARC) - Observer for Monograph on the Evaluation of Carcinogenic Risks to Humans, Volume 134; Aspartame, Methyleugenol, and Ioeugenol, Lyon, France, June 2023.

Session co-chair: "Advances in Thresholds of Toxicological Concern (TTC): Expansion of Databases to Support New Chemical Space." Also presented: "Integration of NAM data to identify chemical substances with endocrine disruptor properties under ECHA/EFSA guidance." 44th Annual Winter Meeting, the Toxicology Forum, Tysons, VA, January 2020.

44th Annual Summer Meeting of the Toxicology Forum (2018). Kinetically Derived Maximum Dose: A Key Initiating Event Impacting Need for Mode of Action Investigations of High-Dose Specific Toxicity (Presenter).

42nd Annual Winter Meeting of the Toxicology Forum (2018). Key Characteristics of Carcinogens: Refining Approaches to Systematic Evaluations of Mechanistic Data (Session Chair); Identification of Mechanistic Data According to Key Characteristics of Carcinogens (KCC) and Review of Studies for Reliability, Relevance, and Activity (Presenter).

American College of Toxicology, Advanced Comprehensive Toxicology Class—Lecture on Kidney Toxicology, August 2017.

42nd Annual Summer Meeting of the Toxicology Forum (2016). Update: Organization and Review of Mechanistic Data According to "Ten Key Characteristics of Carcinogens" (TKCC) (Presenter).

International Agency for Research on Cancer (IARC) — Observer for Monograph on the Evaluation of Carcinogenic Risks to Humans, Volume 115: Some Industrial Chemicals. Lyon, France, 2–9 February 2016.

American College of Toxicology Annual Meeting, November 2013, San Antonio, TX

Session Co-Chair of "Prospective and Retrospective Approaches to Characterize Potential Neurotoxicity"

Invited Speaker of session titled, "Endocrine Disruption Screening — Status of the USEPA and EU programs: State of the Science and Slate for the Future"

Co-Organizer and Session Chair Symposium titled, "Population Diversity Mouse Models and their Use in Toxicology." Toxicology Forum, Aspen, CO, July 2013.

Co-Organizer and Session Chair of a Workshop titled, "Lessons Learned, Challenges, and Opportunities: The US Endocrine Disruptor Screening Program." April 22–23, 2013, Research Triangle Park, NC.

Invited Speaker, Toxicology Forum Meeting, January 2012, "Using a Rat MTBE PBPK Model as a Tool to Evaluate: Mode-of-Action and Route to Route Extrapolation."

Grant reviewer, "Engineered Nanomaterials: Linking Physical and Chemical Properties to Biology (U19)," NIEHS (2010).

Invited Speaker — REACH Symposium, "Fulfilling Technical Requirements." Society of Toxicology presentation (2008).

Ad hoc member of the Voluntary Children's Chemical Evaluation Program (VCCEP) panel to review the assessment of ethylbenzene prepared by the American Chemistry Council (February 2007).

Reviewer on NIEHS Special Emphasis Panel for Absorption, Distribution, Metabolism and Excretion (ADME) Chemical Disposition in Mammals (RFP NIH ES-06-01) (August 17–18, 2006).

EPA Science Advisory Board — Environmental Health Committee, Consultant on the Trichloroethylene Health Risk Assessment: Synthesis and Characterization Review Panel (June 2002).

International Agency for Research on Cancer (IARC) — Working Group Member for Monograph on the Evaluation of Carcinogenic Risks to Humans, Vol. 82, “Traditional Herbal Medicines, Some Mycotoxins, Naphthalene and Styrene” (2002).

International Agency for Research on Cancer (IARC) — Working Group Member for Monograph on the Evaluation of Carcinogenic Risks to Humans, Vol. 77, “Some Industrial Chemicals” (2000).

European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) — Corresponding member on the MTBE Risk Assessment Document (2000).

USEPA. Invited participant and presenter, Workshop on MTBE Pharmacokinetic-Based Extrapolation (May 2000).

Invited participant in a meeting of the ECETOC Task Force on MTBE Risk Assessment and the Finnish Competent Authorities preparing the European Union’s Risk Assessment of MTBE (May 2000).

Invited Speaker, Novartis Crop Protection AG, Basel Switzerland, “Criteria for Evaluating the Ability of a Chemical to Cause α 2u-Globulin-Mediated Renal Tumors in Male Rats,” (November 1999)

Society of Toxicology Annual Meeting — Organizer, Co-Chair, and participant of the symposium titled, “Aliphatic Ethers as Fuel Oxygenates: Health Effects and Regulatory Issues” (March 1999).

Reviewer of NIEHS Superfund Basic Research Program Grant (October 1999).

International Agency for Research on Cancer (IARC) — Working Group Member for Monograph on the Evaluation of Carcinogenic Risks to Humans, Vol. 73, “Some Agents that Cause Tumors of the Kidney, or Urinary Bladder in Rodents and some other Substances” (1998).

Invited Toxicology Scholar Colloquium Speaker, Center for Biochemical Toxicology, University of Connecticut, “The use of mechanistic information in risk assessment-chemical induced α 2u-globulin mediated renal tumors.” May 1998.

Invited Participant — Finnish Institute of Occupational Health, Helsinki, Finland, “Mechanism of MTBE-induced renal tumors in male rats.” October 1998.

Invited Participant – Office of Environmental Health Hazard Assessment, Sacramento, CA, “Mechanism of MTBE-induced tumors in rodents.” July 22, 1998.

European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) — Member of the task force preparing a document on Toxicological Mechanisms (1997–2001).

International Program on Chemical Safety, Methyl Tertiary Butyl Ether, Sponsored by Health Canada. (March 1997).

Workshop to Provide Guidance on the Feasibility and Design of Epidemiologic Studies among Populations Exposed to MTBE. Sponsored by the EPA, Panelist (April 4–5, 1995).

Industry Briefing on Oxyfuel Studies. EPA, Washington D.C., Presenter (April 1995).

Potential Acute Health Effects of Oxygenates in Fuels: A Workshop of the Health Effects Institute Oxygenates Review, Chicago, IL. Presenter — Pharmacokinetics of MTBE Across Species (July 1995).

Oxyfuels Information Needs. EPA, Washington D.C., Presenter (September 1995).

PUBLICATIONS

Borghoff SJ, Heintz MM, Rivera BN, Haws L, Thompson C. 2025. Evaluation of an anti-thyroid mode of action for thyroid follicular cell adenomas in female mice exposed to tertiary butyl alcohol. Regul Toxicol Pharmacol 163(Dec):105936; doi: [10.1016/j.yrtph.2025.105936](https://doi.org/10.1016/j.yrtph.2025.105936).

- Borghoff SJ**, Rivera B, Fitch S, Buerger AN, Choksi N, Franzen A, Vincent MJ, Covington T, Bus J, Rushton E, Lea IA. 2025. Systematic evaluation of the evidence base on methyl tert-butyl ether supporting a lack of concern for carcinogenic hazard in human based on animal cancer studies and mechanistic data. *Curr Res Toxicol* 8:100224; doi: [10.1016/j.crttox.2025.100224](https://doi.org/10.1016/j.crttox.2025.100224).
- Gauthier A, Behymer W, Bare J, Kramer M, Barranco WT, Longtin JP, **Borghoff S**, Jaques A. 2025. Measurement of vinyl acetate monomer in consumer products and modeled estimates of consumer exposure. *J Exp Sci Environ Epidemiol*; doi: [10.1038/s41370-025-00786-y](https://doi.org/10.1038/s41370-025-00786-y). Online ahead of print June 18, 2025. PMID: 40533479.
- Lea IA, Buerger AN, Feifarek D, Mihalchik A, Heintz MM, Haws LC, Nyambego H, Goyak K, Palermo C, **Borghoff SJ**. 2025. Evaluation of the endocrine disrupting potential of Di-isononyl phthalate. *Curr Res Toxicol* 8:100220; doi: [10.1016/j.crttox.2025.100220](https://doi.org/10.1016/j.crttox.2025.100220). Corrigendum 8:100233; doi: [10.1016/j.crttox.2025.100233](https://doi.org/10.1016/j.crttox.2025.100233).
- Lea IA, Feifarek D, Mihalchik A, Heintz M, Haws L, Nyambego H, Goyak K, Palermo C, **Borghoff SJ**. 2025. Evaluation of the endocrine disrupting potential of Di-isodecyl phthalate. *Curr Res Toxicol* 8:100221; doi: [10.1016/j.crttox.2025.100221](https://doi.org/10.1016/j.crttox.2025.100221).
- Thompson CM, Dewhurst N, Moundous D, **Borghoff SJ**, Haws LC, Vasquez MZ. 2024. Assessment of the genotoxicity of tert-butyl alcohol in an in vivo thyroid comet assay. *Environ Mol Mutagen* 65(3–4):129–136; doi: [10.1002/em.22601](https://doi.org/10.1002/em.22601).
- Nelms MD, Antonijevic T, Ring C, Harris DL, Bever RJ, Lynn SG, ... **Borghoff S**, et al. 2024. Chemistry domain of applicability evaluation against existing estrogen receptor high-throughput assay-based activity models. *Front Toxicol* 6:<https://doi.org/10.3389/ftox.2024.1346767>.
- Bever RJ, Edwards SW, Antonijevic T, Nelms MD, Ring C, Harris D, ... **Borghoff S**, Markey KJ. 2024. Optimizing androgen receptor prioritization using high-throughput assay-based activity models. *Front Toxicol* 6:<https://www.frontiersin.org/articles/10.3389/ftox.2024.1347364/full>.
- Henderson RG, Welsh BT, Rogers JM, **Borghoff SJ**, Trexler KR, Bonn-Miller MO, Lefever TW. 2023. Reproductive and developmental toxicity evaluation of cannabidiol. *Food Chem Toxicol* 176:113786. doi: [10.1016/j.fct.2023.113786](https://doi.org/10.1016/j.fct.2023.113786).
- Henderson RG, Lefever TW, Heintz MM, Trexler KR, **Borghoff SJ**, Bonn-Miller MO. 2023. Oral toxicity evaluation of cannabidiol. *Food Chem Toxicol* 176:113778. doi: [10.1016/j.fct.2023.113778](https://doi.org/10.1016/j.fct.2023.113778).
- Borghoff SJ**, Cohen SS, Jiang X, Lea IA, Klaren WD, Chappell GA, Britt JK, Rivera BN, Choksi NY, Wikoff DS. 2023. Updated systematic assessment of human, animal and mechanistic evidence demonstrates lack of human carcinogenicity with consumption of aspartame. *Food Chem Toxicol* 172:113549. doi: [10.1016/j.fct.2022.113549](https://doi.org/10.1016/j.fct.2022.113549).
- Goyak KO, Sarang SS, Franzen A, **Borghoff SJ**, Ryman-Rasmussen JP. 2022. Adverse outcome pathway (AOP): α2u-globulin nephropathy and kidney tumors in male rats. *Crit Rev Toxicol* 52(5):345-357. doi: [10.1080/10408444.2022.2082269](https://doi.org/10.1080/10408444.2022.2082269).
- Lea IA, Pham LL, Antonijevic T, Thompson C, **Borghoff SJ**. 2022. Assessment of the applicability of the threshold of toxicological concern for per- and polyfluoroalkyl substances. *Regul Toxicol Pharmacol* 133:105190. doi: [10.1016/j.yrtph.2022.105190](https://doi.org/10.1016/j.yrtph.2022.105190).
- Gentry R, Greene T, Chappell G, Lea I, **Borghoff S**, Yang C, Rathman J, Ribeiro JV, Hobocienski B, Mostrag A, Rodricks J, Clewell H. 2021. Integration of evidence to evaluate the potential for neurobehavioral effects following exposure to USFDA-approved food colors. *Food Chem Toxicol* 151:112097. doi: [10.1016/j.fct.2021.112097](https://doi.org/10.1016/j.fct.2021.112097).
- Gentry R, Rodricks J, Clewell H, Greene T, Chappell G, Lea I, **Borghoff S**, Yang C, Rathman J, Ribeiro JV, Hobocienski B, Mostrag A. 2021. RE: Response to the Office of Environmental Health Hazard Assessment on comments related to Gentry et al. (2021). *Food Chem Toxicol* 152:112202. doi: [10.1016/j.fct.2021.112202](https://doi.org/10.1016/j.fct.2021.112202).

Black MB, Andersen ME, Pendse SN, **Borghoff SJ**, Streicker M, McMullen PD. 2021. RNA-sequencing (transcriptomic) data collected in liver and lung of male and female B6C3F1 mice exposed to various dose levels of 4-methylimidazole for 2, 5, or 28 days. Data in Brief 38:107420. doi: 10.1016/j.dib.2021.107420.

Borghoff SJ, Fitch SE, Black MVB, McMullen PD, Andersen ME, Chappell GA. 2021. A systematic approach to evaluate plausible modes of [action] for mouse lung tumors in mice exposed to 4-methylimidazole. Regul Toxicol Pharmacol 124:104977. doi: 10.1016/j.yrtph.2021.104977.

Chappell GA, Heintz MM, **Borghoff SJ**, Doepker CL, Wikoff DS. 2021. Lack of potential carcinogenicity for steviol glycosides — Systematic evaluation and integration of mechanistic data into the totality of evidence. Food Chem Toxicol 150:112045. doi: 10.1016/j.fct.2021.112045.

Chappell GA, Britt JK, **Borghoff SJ**. 2020. Systematic assessment of mechanistic data for FDA-certified food colors and neurodevelopmental processes. Food Chem Toxicol 140:111310. doi: 10.1016/j.fct.2020.111310.

Chappell GA, Wikoff DS, Doepker CL, **Borghoff SJ**. 2020. Lack of potential carcinogenicity for acesulfame potassium — Systematic evaluation and integration of mechanistic data into the totality of the evidence. Food Chem Toxicol 141:111375. doi: 10.1016/j.fct.2020.111375.

Pham LL, **Borghoff SJ**, Thompson CM. 2020. Comparison of threshold of toxicological concern (TTC) values to oral reference dose (RfD) values. Regul Toxicol Pharmacol 113:104651. doi: 10.1016/j.yrtph.2020.104651.

Chappell GA, **Borghoff SJ**, Pham L, Doepker CL, Wikoff DS. 2019. Lack of potential carcinogenicity for sucralose — Systematic evaluation and integration of mechanistic data into the totality of the evidence. Food Chem Toxicol 135:110898. doi: 10.1016/j.fct.2019.110898.

Wikoff DS, Chappell GA, Fitch S, Doepker CL, **Borghoff SJ**. 2019. Lack of potential carcinogenicity for aspartame — Systematic evaluation and integration of mechanistic data into the totality of the evidence. Food Chem Toxicol 135:110866. doi: 10.1016/j.fct.2019.110866.

van de Ligt J, **Borghoff SJ**, Yoon M, Ferguson LJ, DeMaio W, McClanahan RH. 2019. Nondetectable or minimal detectable residue levels of N-(n-butyl) thiophosphoric triamide in bovine tissues and milk from a 28-d NBPT dosing study. Transl Anim Sci 3(4): 1606-1616. doi: 10.1093/tas/txz153.

Wikoff DS, Rager JE, Chappell GA, Fitch S, Haws L, **Borghoff SJ**. 2018. A framework for systematic evaluation and quantitative integration of mechanistic data in assessments of potential human carcinogens. Toxicol Sci 167(2):322–335. doi: 10.1093/toxsci/kfy279.

Borghoff SJ, Fitch S, Rager JE, Huggett D. 2018. A hypothesis-driven weight-of-evidence analysis to evaluate potential endocrine activity of perfluorohexanoic acid. Regul Toxicol Pharmacol 99:168–181.

Harrill AH, **Borghoff S**, Zorrilla L, Blystone C, Kissling GE, Malarkey D, Shockley K, Travlos G, DeVito MJ. 2018. NTP Research Report on baseline characteristics of Diversity Outbred (J:DO) mice relevant to toxicology studies. National Toxicology Program Research Report 6, Research Triangle Park, NC. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK525004/>.

Klaren WD, Ring C, Harris MA, Thompson CM, **Borghoff S**, Sipes NS, Hsieh J-H, Auerbach SS, Rager JE. 2018. Identifying attributes that influence *in vitro*-to-*in vivo* concordance by comparing *in vitro* Tox21 bioactivity versus *in vivo* DrugMatrix transcriptomic responses across 130 chemicals. Toxicol Sci 120:709–723. doi: 10.1093/toxsci/kfy220.

Proctor DM, Suh M, Chappell G, **Borghoff SJ**, Thompson CM, Wiench K, Finch L, Ellis-Hutchings R. 2018. An adverse outcome pathway (AOP) for forestomach tumors induced by non-genotoxic initiating events. Regul Toxicol Pharmacol 96:30–40. doi: 10.1016/j.yrtph.2018.04.016.

Suh M, Proctor DM, Chappell G, Rager JE, Thompson CM, **Borghoff S**, Finch L, Ellis-Hutchings R, Wiench K. 2018. A review of the genotoxic, mutagenic, and carcinogenic potentials of several lower acrylates. Toxicology 402–403:50–67. doi: 10.1016/j.tox.2018.04.006.

Thompson CT, Suh M, Chappell G, **Borghoff S**, Ellis-Hutchings R, Wiench K, Finch L, Proctor DM. 2018. Assessment of the mode of action underlying development of forestomach tumors in rodents following oral exposure to ethyl acrylate and relevance to humans. *Regul Toxicol Pharmacol* 96:178–189. doi: 10.1016/j.yrtph.2018.05.006.

Borghoff SJ, Ring C, Banton M, Leavens TL. 2016. Physiologically based pharmacokinetic model for ethyl tertiary-butyl ether and tertiary-butyl alcohol in rats: Contribution of binding to α 2u-globulin in male rats and high-exposure nonlinear kinetics to toxicity and cancer outcomes. *J Appl Toxicol* 37(5):621–640. doi 10.1002/jat.3412

Hughs BJ, Johnson T, Lynch A, **Borghoff SJ**, Green S, Mensing T, Sarang SS, LeBaron MJ. 2016. Methyl isobutyl ketone-induced hepatocellular carcinogenesis in B6C3F1 mice: A constitutive androstane receptor (CAR)-mediated mode of action. *Regul Toxicol Pharmacol* 81:421–429.

Wikoff DS, Rager JE, Haws LC, **Borghoff SJ**. 2016. A high dose mode of action for Tetrabromobisphenol A-induced uterine adenocarcinomas in Wistar Han rats: A critical evaluation of key events in an adverse outcome pathway framework. *Regul Toxicol Pharmacol* 77:143–159. doi: 10.1016/j.yrtph.2016.01.018.

Borghoff SJ, Wikoff D, Harvey S, Haws L. 2016. Dose- and time-dependent changes in tissue levels of tetrabromobisphenol A (TBBPA) and its sulfate and glucuronide conjugates following repeated administration to female Wistar Han Rats. *Toxicol Rep* 155:104–108. doi:10.1016/j.toxrep.2016.01.007.

Borghoff SJ, Poet TS, Green S, Davis J, Hughes B, Mensing T, Sarang SS, Lynch AM, Hard GC. 2015. Methyl isobutyl ketone exposure-related increases in specific measures of α 2u-globulin (α 2u) nephropathy in male rats along with in vitro evidence of reversible protein binding. *Toxicology* 333:1–13.

Wikoff D, Thompson C, Perry C, White M, **Borghoff S**, Fitzgerald L, Haws LC. 2015. Development of toxicity values and exposure estimates for tetrabromobisphenol A (TBBPA): Application in a margin of exposure assessment. *J Appl Toxicol* 35(11):1292–1308. doi: 10.1002/jat.3132.

Faber W, Kirkpatrick D, Coder P, Li A, **Borghoff S**, Banton M. 2014. Subchronic, reproductive, and maternal toxicity studies with tertiary butyl acetate (TBAC). *Regul Toxicol Pharmacol* 68:332–342.

Juberg DR, **Borghoff SJ**, Becker RA, Casey W, Hartung T, Holsapple MP, Marty MS, Mihaich EM, Van Der Kraak G, Wade MG, et al. 2014. Lessons learned, challenges, and opportunities: The U.S. Endocrine Disruptor Screening Program. *Altex* 31(1):63–8.

Becker RA, Bergfelt DR, **Borghoff S**, Davis JP, Hamby BT, O'Connor, J.C., Kaplan, A.M., Sloan, C.S., Tyl, R.W., Wade, M., and Marty, M.S. 2012. Inter-laboratory study comparison of the 15-day intact adult male rat screening assay: Evaluation of an anti-thyroid chemical and a negative control chemical. *Birth Defects Res (Part B)* 95:63–78.

Borghoff SJ, Parkinson H, Leavens TL. 2010. Physiologically based pharmacokinetic rat model for methyl tertiary-butyl ether; comparison of selected dose metrics following various MTBE exposure scenarios used for toxicity and carcinogenicity evaluation. *Toxicology* 275(1-3):79–91.

Borghoff SJ, Hard GC, Berdasco NM, Gingell R, Green SM, Gullledge W. 2009. Methyl isobutyl ketone (MIBK) induction of α 2u-globulin nephropathy in male, but not female rats. *Toxicology* 258:131–138.

Leavens TL, **Borghoff SJ**. 2009. Physiologically based pharmacokinetic model of methyl tertiary butyl ether and tertiary butyl alcohol dosimetry in male rats based on binding to α 2u-globulin. *Toxicol Sci* 109(2):321–335.

Clewell RA, Kremer JJ, Williams CC, Campbell JL, Jr., Andersen ME, **Borghoff SJ**. 2009. Kinetics of selected di-n-butyl phthalate metabolites and fetal testosterone following repeated and single administration in pregnant rats. *Toxicology* 255(1-2):80–90.

Clewell RA, Kremer JJ, Williams CC, Campbell JL, Jr., Andersen ME, **Borghoff SJ**. 2008. Tissue exposures to free and glucuronidated monobutylphthalate in pregnant and fetal rat following exposure to di-n-butylphthalate: Evaluation with a PBPK model. *Toxicol Sci* 103(2):241–259.

- Liao KH, Tan Y, Conolly RB, **Borghoff SJ**, Gargas ML, Andersen ME, Clewell HJ. 2007. Bayesian estimation of pharmacokinetic and pharmacodynamic parameters in a mode-of-action-based cancer risk assessment for chloroform. *Risk Anal* 27:1535–1551.
- Ferguson LJ, Lebetkin EH, Lih FB, Tomer KB, Parkinson HD, **Borghoff SJ**, Burka LT. 2007. 14C-Labeled pulegone and metabolites binding to alpha α 2u-globulin in kidneys of male F-344 rats. *J Toxicol Environ Health A* 70:1416–1423.
- Gaido KW, Hensley JB, Liu D, Wallace DG, **Borghoff S**, Johnson KJ, Hall SJ, Boekelheide K. 2007. Fetal mouse phthalate exposure shows that gonocyte multinucleation is not associated with decreased testicular testosterone. *Toxicol Sci* 97(2):491–503.
- Cruzan G, **Borghoff SJ**, de Peyster A, Hard GC, McClain M, McGregor DB, Thomas MG. 2007. Methyl tertiary-butyl ether mode-of-action for cancer endpoints in rodents. *Regul Toxicol Pharmacol* 47:156–165.
- Soucy NV, Parkinson HD, Sochaski MA, **Borghoff SJ**. 2006. Kinetics of genistein and conjugated metabolites in pregnant Sprague-Dawley rats following single and repeated administration of genistein. *Toxicol Sci* 90:230–240.
- Schlosser PM, **Borghoff SJ**, Coldham NG, David JA, Ghosh SK. 2006. Physiologically based pharmacokinetic modeling of genistein in rats, Part I: Model development. *Risk Anal* 26:483–500.
- Kremer JJ, Williams CW, Parkinson HP, Borghoff SJ. 2005. Pharmacokinetics of monobutylphthalate, the toxic metabolite of di-n-butylphthate, in pregnant rats. *Toxicol Lett* 159:144–153.
- Bauer AK, Faiola B, Abernethy DJ, Marchan R, Pluta LJ, Wong VA, Roberts K., Jaiswal AK, Gonzalez FJ, Butterworth BE, **Borghoff SJ**, Parkinson HD, Everitt JI, Recio L. 2003. Genetic susceptibility to benzene-induced toxicity: Role of NAD(P)H oxidoreductase-1. *Cancer Res* 63:929–935.
- Bauer AK, Faiola B, Abernethy DJ, Marchan R, Pluta LJ, Wong VA, Gonzalez FJ, Butterworth BE, **Borghoff SJ**, Everitt JI, Recio L. 2003. Male mice deficient in microsomal epoxide hydrolase are not susceptible to benzene-induced toxicity. *Toxicol Sci* 72:201–209.
- Licata AC, Dekant W, Smith CE, **Borghoff SJ**. 2001. A physiologically-based pharmacokinetic model for methyl tert-butyl ether in humans: Implementing sensitivity and variability analysis. *Toxicol Sci* 62:191–204.
- Borghoff SJ**, Prescott JS, Poet TS, Janszen D, Wong B, Everitt JI. 2001. α 2u-Globulin nephropathy, renal cell proliferation and dosimetry of inhaled tertbutyl alcohol in male and female Fischer 344 rats. *Toxicol Sci* 61:176–186 (highlighted paper).
- Williams TM, **Borghoff SJ**. 2001. Characterization of tert-butyl alcohol binding to alpha2u-globulin in F-344 rats. *Toxicol Sci* 62(2):228–235.
- Williams TM, **Borghoff SJ**. 2000. Induction of testosterone biotransformation enzymes following oral administration of methyl tert-butyl ether to male Sprague-Dawley rats. *Toxicol Sci* 57:147–155.
- Williams TM, Cattley RC, **Borghoff SJ**. 2000. Alterations in endocrine responses in male Sprague-Dawley rats following oral administration of methyl tert-butyl ether. *Toxicol Sci* 54:168–176.
- Prescott-Mathews JS, Poet TS, **Borghoff SJ**. 1999. Evaluation of the in vivo interaction of methyl tert-butyl ether with α 2u-globulin in male F-344 rats. *Toxicol Appl Pharmacol* 157:60–67.
- Collins AS, Sumner SCJ, **Borghoff SJ**, Medinsky MA. 1999. A physiological model for tert-amyl methyl ether and tert-amyl alcohol: Hypothesis testing of model structures. *Toxicol Sci* 49:15–28.
- Poet TS, Valentine JL, **Borghoff SJ**. 1997. Pharmacokinetics of tertiary butyl alcohol in male and female Fischer 344 rats. *Toxicol Lett* 92:179–186.
- Poet TS, **Borghoff SJ**. 1997. In vitro uptake of methyl tert-butyl ether in male rat kidney: Use of a two-compartment model to describe protein interactions. *Toxicol Appl Pharmacol* 145:340–348.

- Prescott-Mathews JS, Wolf DC, Wong BA, **Borghoff SJ**. 1997. Methyl tert-butyl ether causes α 2uglobulin nephropathy and enhanced renal cell proliferation in male Fischer-344 rats. *Toxicol Appl Pharmacol* 143:301–314.
- Dix KJ, Kedderis GL, **Borghoff SJ**. 1997. Vehicle-dependent oral absorption and target tissue dosimetry of chloroform in male rats and female mice. *Toxicol Lett* 91:197–209.
- Borghoff SJ**, Murphy JE, Medinsky MA. 1996. Development of a physiologically based pharmacokinetic model for methyl tertiary-butyl ether and tertiary-butanol in male Fischer 344 rats. *Fundam Appl Toxicol* 30:264–275.
- Butterworth BE, Templin MV, **Borghoff SJ**, Conolly RB, Kedderis GL, Wolf DC. 1995. The role of regenerative cell proliferation in chloroform-induced cancer. *Toxicol Lett* 82/83:23–26.
- Butterworth BE, **Borghoff SJ**, Conolly RB, Kedderis GL, Wolf DC. 1995. Carcinogenic risks associated with chloroform. *Fundam Appl Toxicol* 28:158–160.
- Borghoff SJ**, Gargas M, Andersen ME, Conolly RB. 1995. A mechanistic-based dosimetry model for 2,4,4-trimethyl-2-pentanol-induced α 2u-globulin nephropathy in the kidneys of male rats. *Fundam Appl Toxicol* 25:124–137.
- Wilke A, Dorman D, **Borghoff SJ**. 1994. In vitro nephrotoxicity of α 2u-globulin, 2,5-dichlorophenol, and 2,4,4-trimethyl-2-pentanol to rat proximal tubule fragments. *In Vitro Toxicol* 7:4.
- Borghoff SJ**, Lehman-McKeeman LD, Short BG, Hard GC, Swenberg JA. 1993. Critique of R. Melnick's "An alternative hypothesis on the role of chemically induced protein droplet (alpha 2u-globulin) nephropathy in renal carcinogenesis." *Regul Toxicol Pharmacol* 18(2):357–364.
- Borghoff SJ**, Lagarde WH. 1993. Assessment of binding of 2,4,4-trimethyl-2-pentanol to lowmolecular weight proteins isolated from kidneys of male rats and humans. *Toxicol Appl Pharmacol* 119:228–235.
- Borghoff SJ**, Youtsey NA, Swenberg JA. 1992. Comparison between European High Test and PS-6 gasoline in their ability to cause α 2u-globulin nephropathy and renal cell proliferation. *Toxicol Lett* 63:21–33.
- Borghoff SJ**, Miller A, Bowen P, Swenberg JA. 1991. Characteristics of chemical binding to α 2uglobulin in vitro — Evaluating structure activity relationships. *Toxicol Appl Pharmacol* 107:228–238.
- Borghoff SJ**, Short BG, Swenberg JA. 1990. Biochemical mechanisms and pathobiology of alpha 2u-globulin nephropathy. *Annu Rev Pharmacol Toxicol* 30:349–367.
- Swenberg JA, Short B, **Borghoff SJ**, Strasser J, Charbonneau M. 1989. The comparative pathobiology of α 2u-globulin nephropathy. *Toxicol Appl Pharmacol* 97:35–46.
- Borghoff SJ**, Stefanski SA, Birnbaum LS. 1988. The effect of age on the glucuronidation and toxicity of 4,4'-thiobis(6-t-butyl-m-cresol). *Toxicol Appl Pharmacol* 92:453–466.
- Borghoff SJ**, Birnbaum LS. 1986. Age-related changes in the metabolism and excretion of allyl isothiocyanate: A model compound for glutathione conjugation. *Drug Metab Dispos* 14:417–422.
- Borghoff SJ**, Birnbaum LS. 1985. Age-related changes in glucuronidation and deglucuronidation in liver, small intestine, lung, and kidney of male Fischer rats. *Drug Metab Dispos* 13:62–67.

BOOK CHAPTERS AND REVIEWS

- Lea IA, **Borghoff SJ**, Travlos GS. 2016. Electrolytes, blood gases and acid-base balance. In: Kurtz DA, Prescott JS, Travlos G (eds), Loeb and Quimby's Clinical Chemistry of Laboratory Animals, 3rd Edition. CRC Press.
- Borghoff S**. 2004. Toxicology, education and careers. In: Wexler P (ed), Encyclopedia of Toxicology, 2nd Edition. Elsevier.

Borghoff SJ, Williams TM. 2000. Species-specific tumor responses following exposure to methyl tert butyl ether. CIIT Activities 20.

Borghoff SJ. 1997. Commentary (Response to an article by J.H. Mennear). Toxicol Ecotoxicol News 4(5):147.

McClellan RO, **Borghoff SJ**, Casanova M, Conolly RB, Heck Hd'A, Morgan KT, Recio L. 1997. Can mechanistic information reduce the uncertainty in cancer risk assessment? In: Bisby JA, Humphry NF, Rhodes D, Russell RA (eds), Occupational Health in the Chemical Industry. Selected Papers from the XXI Medichem Congress (October 18-21, 1994, Melbourne, Australia), pp. 57–79. World Health Organization.

Borghoff SJ. 1996. Research approaches on mechanisms of chronic toxicity. The Toxicology Forum, Annual Winter Meeting, Caset Assoc., Ltd, pp. 153–162.

Borghoff SJ, Prescott-Mathews JS, Poet TS. 1996. The mechanism of male rat kidney tumors induced by methyl tert-butyl ether and its relevance in assessing human risk. CIIT Activities 15.

Prescott-Mathews JS, **Borghoff SJ**. 1996. Methyl tert-butyl ether and tert-butyl alcohol-induced α 2unephropathy in male F-344 rats. Proceedings of the American College of Veterinary Pathology.

Borghoff SJ. 1993. α 2u-Globulin-mediated male rat nephropathy and kidney cancer: Relevance to human risk assessment. CIIT Activities 13.

Borghoff SJ, Lehman-McKeeman LD, Short BG, Hard GC, Swenberg JA. 1993. Critique of R. Melnick's "An alternative hypothesis on the role of chemically-induced protein droplet α 2u-globulin nephropathy in renal carcinogenesis." Regul Toxicol Pharmacol 18:357–364.

Borghoff SJ, Andersen ME, Conolly RB. 1991. Protein nephropathy and kidney cancer in male rats: Qualitative and quantitative issues and human relevance. CIIT Activities 11.

Borghoff SJ, Short BG, Swenberg JA. 1990. Biochemical mechanisms and pathobiology of α 2uglobulin nephropathy. Annu Rev Pharmacol Toxicol 30:349–367.

Borghoff SJ, Swenberg JA. 1989. Nongenotoxic carcinogens — Mechanism of α 2u-globulin nephropathy. International Congress of Toxicology, Brighton, England, pp. 303-309.

SELECTED ABSTRACTS AND PRESENTATIONS

Covington TR, **Borghoff SJ**, Brorby GP, Doepker CL, Wikoff DS, Franzen AC. Using IVIVE to address systemic exposure challenges in genotoxicity testing of complex mixtures. Poster Session PO-41, American Society for Cellular and Computational Toxicology (ASCCT) 14th Annual Meeting, Gaithersburg, MD, October 2025.

Borghoff SJ, Rivera BN, Fitch S, Buerger A, Choksi N, Franzen A, Bus J, Rushton EK, Lea I. Systematic evaluation of the evidence base on methyl tert-butyl ether for carcinogenic potential in humans; Low concern based on animal cancer studies and mechanistic data. Abstract 4702, Society of Toxicology 64th Annual Meeting, Orlando, FL, March 2025.

Buerger AN, Vincent MJ, Fitch S, Rushton EK, **Borghoff SJ**. Evaluation of potential obesogenicity through a mode of action approach: A case study with MTBE. Abstract 3928, Society of Toxicology 64th Annual Meeting, Orlando, FL, March 2025.

Cook B, Nelms M, Harris D, Bever RJ, Lynn SG, Williams D, **Borghoff S**, Edwards SW, Markey K. Identifying structural overlap between EDSP universe of chemicals and ToxCast/Tox21 using chemical clustering and uniform manifold approximation and projection. Abstract 4034, Society of Toxicology 64th Annual Meeting, Orlando, FL, March 2025.

Rivera BN, Lea IA, Fitch S, Choksi N, Franzen A, Bus J, Rushton EK, **Borghoff SJ**. Systematic evaluation of the evidence base on ethyl tert-butyl ether and tert-butyl alcohol for carcinogenic potential in humans: Low concern based on animal cancer studies and mechanistic data. Abstract 4697, Society of Toxicology 64th Annual Meeting, Orlando, FL, March 2025

Cook B, Nelms MD, Harris D, Bever RJ, Lynn SC, **Borghoff S**, et al. Clustering chemicals for predicting behavior and hazards: Insights from the endocrine disruptor screening program (EDSP) universe of chemicals. American Society of Cellular and Computational Toxicology Annual Meeting, Research Triangle Park, NC, October 2024.

Covington TR, **Borghoff SJ**, Bacigalupi L, O'Neal S, Cook B, Nelms M, et al. Prediction of chemical suitability for screening in a high-throughput assay platform using an in silico mass balance model. American Society of Cellular and Computational Toxicology Annual Meeting, Research Triangle Park, NC, October 2024.

Holt JR, Chew RF, Bunnage E, Lea I, **Borghoff SJ**, Sayer R, et al. Categorizing articles for environmental health systematic evidence mapping: A zero-shot machine learning approach using large language models. American Society of Cellular and Computational Toxicology Annual Meeting, Research Triangle Park, NC, October 2024.

Lea IA, **Borghoff SJ**, Chew R, Bell S, Edwards S, Vasko J, et al. Leveraging computational tools for enhanced human-in-the-loop systematic literature reviews. American Society of Cellular and Computational Toxicology Annual Meeting, Research Triangle Park, NC, October 2024.

Borghoff SJ, Feifarek D, Mihalchik A, Heintz M, Haws L, Nyambego H, Goyak K, Lea IA. Evaluation of the endocrine disrupting potential of di-isononyl phthalate. Abstract 3931, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.

Lea IA, Feifarek D, Mihalchik A, Heintz M, Haws L, Nyambego H, Goyak K, **Borghoff SJ**. Evaluation of the endocrine disrupting potential of di-isodecyl phthalate. Abstract 3930, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.

Lynn SG, Lea IA, Urban J, **Borghoff SJ**, Wikoff D, Fitch S, Perry C, Choksi N, Britt J, Heintz M, Klaren W, et al. Development and application of systematic approach to inventory and interrogate thyroid hormone network information. Abstract 4357, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.

Nelms M, Antonijevic T, Ring C, Harris D, Bever RJ, ... **Borghoff S**, et al. Chemistry domain of applicability evaluation of estrogen receptor high-throughput assay-based activity models. Abstract 4380, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.

Edwards S, Antonijevic T, Nelms M, Ring C, Harris D, ... **Borghoff S**, Markey K. Development and application of a systematic approach to inventory and interrogate thyroid hormone network information. Abstract 4381, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.

Lea IA, Heintz MM, Feifarek D, Haws LC, **Borghoff SJ**. Weight-of-evidence evaluation of endocrine activity for di-isodecyl phthalate (DIDP) and di-isononyl phthalate (DINP). Poster presented at Society of Toxicology 62nd Annual Meeting, Nashville, TN, March 2023.

Wikoff D, Edwards S, Angrish M, Baumgartner, Bever R, **Borghoff S**, Chappell G, Chew R, Fitch S, Hench G, Hamernik K, Henderson D, Kirk A, Lea I, Mandel M, Payne L, Shapiro S, Urban J, Williams D, Markey K. Application of systematic methods to characterize thyroid adverse outcome pathways (AOPs). Presented at American Society for Cellular and Computational Toxicology 10th Annual Meeting, Virtual, October 2021.

Borghoff SJ. Integration of NAM data to identify chemical substances with endocrine disruptor properties under ECHA/EFSA guidance. Presentation to Toxicology Forum virtual meeting, August 2020.

Franzen A, **Borghoff SJ**. An adverse outcome pathway for renal tumors in male rats through chemical induction of α 2u-globuline (α 2u) nephropathy (α 2u-N). Poster for Society of Toxicology 59th Annual Meeting, Virtual, 2020.

Borghoff S, Fitch S, Britt J, Franke K, Wikoff D. Application of the EFSA/ECHA endocrine disruption guidance as a framework for evidence integration in a weight-of-evidence (WoE) analysis for oxybenzone (BP-3). Poster at Evidence Integration in Chemical Assessments: Challenges Faced in Developing and Communicating Human Health Effect Conclusions, National Academies of Sciences, Engineering, and Medicine, Washington, DC, June 2019.

Borghoff SJ, Fitch S, Huggett, Wikoff D. A hypothesis-driven weight-of-evidence analysis to evaluate potential endocrine disrupting properties of perfluorohexanoic acid (PFHxA). 2019. Poster at Society of Toxicology 58th Annual Meeting, Baltimore, MD, March 2019.

McIntyre B, Zorrilla L, **Borghoff, S**, Foster P. Assessment of avobenzone, ensulizole, homosalate, and padimate-O in endocrine disruptor screening panel studies. Poster at Society of Toxicology 58th Annual Meeting, Baltimore, MD, March 2019.

Borghoff S, Wikoff D, Urban JD, Rager J. A systematic approach to identify plausible mode-of-actions (MOA) for an increased incidence of lung tumors in mice with chronic exposure to 4-methylimidazole (4-MEI). Society of Toxicology 57th Annual Meeting, San Antonio, TX, March 2018.

Wikoff DS, Rager JE, Harvey S, Haws L, Chappell G, **Borghoff S**. Development and refinement of a framework for quantitative consideration of study quality and relevance in the evaluation of mechanistic data based on Key Characteristics of Carcinogens. Society of Risk Analysis Annual Meeting, Arlington, VA, December 2017.

Huggett D, Harvey S, Korzeniowski S, **Borghoff SJ**. The potential for 6:2 FTOH to modulate the endocrine system in wildlife: A hypothesis driven weight of evidence analysis across endocrine pathways. SETAC North America 38th Annual Meeting, Minneapolis, MN, November 2017.

Borghoff SJ, Harvery, S, Korzeniowski S, Huggett D. The potential for PFHxA to modulate the endocrine system in wildlife: A hypothesis driven weight of evidence analysis across endocrine pathways. SETAC North America 38th Annual Meeting, Minneapolis, MN, November 2017.

Borghoff SJ, Ring C, Banton MI, Leavens TL. Ethyl tertiary butyl ether (ETBE) and tertiary butyl alcohol (TBA) physiologically based pharmacokinetic (PBPK) model in rats: Contribution of binding to α 2u-globulin and non-linear kinetics to kidney and liver responses in rats. Poster presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.

Wikoff DS, Rager J, Harvey S, Haws L, Chappell G, **Borghoff S**. Framework for quantitative consideration of study quality and relevance in the systematic evaluation of mechanistic data per the Ten Key Characteristics of Carcinogens. Poster presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.

DeVito MJ, **Borghoff SJ**, Zorrilla L, Shockley KR, Kissling G, Travlos G. The effects of a high fat (HF) diet on male diversity of outbred (DO) mice. Presented at Society of Toxicology 55th Annual Meeting, New Orleans, LA, March 2016.

Wikoff D, **Borghoff S**, Rager JE, Haws LC. Human relevance assessment of tetrabromobisphenol-A (TBBPA) induced uterine adenocarcinomas: Mode of action dependent on high dose molecular initiating event (MIE). Presented at Society of Toxicology 55th Annual Meeting, New Orleans, LA, March 2016.

Borghoff S, Wikoff D, Rager JE, Haws LC. Tetrabromobisphenol-A (TBBPA): Dose- and time-dependent changes in plasma TBBPA and its conjugates over 28 days of administration. Presented at Society of Toxicology 55th Annual Meeting, New Orleans, LA, March 2016.

Wikoff D, White MC, **Borghoff SJ**, Haws LC. Evaluation of tetrabromobisphenol A (TBBPA)-induced endocrine-related target gene activity using high-throughput screening data from ToxCast. Presented at Society of Toxicology 54th Annual Meeting, San Diego, CA, March 2015.

Borghoff S, Wikoff D, White MC, Thompson CM, Haws LC. Identification of the molecular initiating event (MIE) for TBBPA-induced uterine tumors in the framework of an adverse outcome pathway (AOP). Presented at Society of Toxicology 54th Annual Meeting, San Diego, CA, March 2015.

Hughes BJ, LeBaron MJ, Thomas J, Kan HL, Lynch AM, **Borghoff SJ**, Green S, Mensing T, Sarang SS, Smulders CJGM. Activation of CAR and PXR nuclear receptors in the liver of MIBK-exposed mice. Presented at Society of Toxicology 54th Annual Meeting, San Diego, CA, March 2015.

Borghoff SJ, Hard GC, Poet TS, Davis J, Green S, Hughes B, Mensing T, Sarang SS. 2014. Methyl isobutyl ketone (MIBK) induces an exposure-related increase in measures of α 2u-globulin (α 2u) nephropathy in male but not female F344 rats. The Toxicologist 138(1):[Abstract no. 2059].

Haws LC, Thompson C, Perry C, White M, Fitzgerald L, **Borghoff S**, Wikoff D. 2014. Development of noncancer based toxicity factors and daily dose estimates for TBBPA. The Toxicologist 138(1) [Abstract no. 623].

Wikoff D, Thompson C, Perry C, White M, Fitzgerald L, **Borghoff S**, Haws LC. 2014. Development of an oral cancer slope factor and lifetime average daily dose estimates for TBBPA. The Toxicologist 138(1) [Abstract no. 622].

Zorrilla L, **Borghoff SJ**, Osimitz TG. 2013. Permethrin does not have endocrine disrupting properties as evaluated by the US EPA's Endocrine Disruptor Screening Program (EDSP) in vivo assays. The Toxicologist 132(1) [Abstract no. 102].

Borghoff SJ, Streicker MA, Painter T, French JE. 2010. Evaluating the sensitivity of 6 different F1 hybrid mice for genetic susceptibility to ionizing radiation. The Toxicologist 114(1) [Abstract no. 591]. Platform presentation.

Borghoff S, Davis J, Hackett T, Sproul P, Moser G. Endocrine disruptor screening program: Demonstrating laboratory proficiency in conducting Tier 1 mammalian in vivo assays. American College of Toxicology 30th Annual Meeting, poster presentation P36, Palm Springs, CA, 2009.

Davis J, Moser G, Iverson B, **Borghoff S**. Evaluating the potential endocrine disrupting activity of DE-71 in the intact adult male rat screening assay. American College of Toxicology 30th Annual Meeting, poster presentation P58, Palm Springs, CA, 2009.

Haines WR, **Borghoff SJ**, Malarkey DE, Painter TJ, Travlos GS, Thayer K, Melnick RL. 2009. Precision-organ slice technology to evaluate liver toxicity of perfluorinated compounds (PFCs). The Toxicologist 108(S-1):87 [Abstract no. 420].

Borghoff S, Hobbs C, Shepard K, Travlos GS. 2008. Measurement of cardiac troponin T (cTnT) in rat serum: Comparing two electrochemiluminescent (ECL) platforms. The Toxicologist 81(1) [Abstract no. 1655].

Hand GC, Berdasco N, Gingell R, Green S, Gullledge W, **Borghoff S**. 2008. Methyl isobutyl ketone (MIBK) induced α 2u-globulin (α 2u) nephropathy in male and female F344 rats. The Toxicologist 81(1) [Abstract no. 465].

Borghoff S. 2008. Fulfilling technical requirements of REACH. [Abstract no. 2361]. Symposium presentation.

Bermudez E, Parkinson H, **Borghoff SJ**. 2007. Methyl tertiary butyl ether (MTBE) 14-day drinking water study in Wistar rats. The Toxicologist 81(1) [Abstract no. 1515].

Schlosser PM, **Borghoff SJ**, Coldham NG, David JA, Garcia R, Setzer R, Ghosh SK. 2007. Bayesian PBPK modeling of genistein in rats. The Toxicologist 80(1) [Abstract no. 2014].

Clewell RA, **Borghoff SJ**, Andersen ME. 2007. Application of a unified PBPK model to two kinetically distinct phthalate esters — DBP and DEHP. The Toxicologist 80(1) [Abstract no. 1682].

Gaido K, Hensley JB, Liu D, Wallace DG, **Borghoff S**, Johnson KJ, Hall SJ, Boekelheide K. 2006. Fetal mouse phthalate exposure shows that gonocyte multinucleation is not associated with decreased testicular steroidogenesis. The Toxicologist 81(1) [Abstract no. 1859].

Soucy NV, Parkinson HD, **Borghoff SJ**. 2006. Placental gene expression in response to high levels of unconjugated genistein in placenta of rats administered genistein. The Toxicologist 80(1) [Abstract no. 168].

Clewell RA, Kremer J, Andersen M, **Borghoff SJ**. 2006. Using a PBPK model to explore mechanisms of observed pharmacokinetic differences of phthalates across life-stages in rats. The Toxicologist 80(1) [Abstract no. 1270].

Leavens T, **Borghoff S**. 2006. Route extrapolation of MTBE pharmacokinetics in rats. The Toxicologist 80(1) [Abstract no. 1272].

Soucy NV, Parkinson HD, Sochaski MA, **Borghoff SJ**. 2005. Maternal and fetal disposition of genistein glucuronide and sulfate conjugates following 14-day in utero exposure to genistein. The Toxicologist 79(1) [Abstract no. 1228].

Kremer JJ, Clewell RA, **Borghoff SJ**. 2005. Prediction of di-n-butylphthalate (DBP) levels in pregnant rats using a physiologically-based pharmacokinetic (PBPK) model. The Toxicologist 79(1) [Abstract no. 862].

Borghoff S, Parkinson HD, Ross SM, Gaido K, Sochaski M. 2004. Activation of human estrogen receptors in HepG2 cells by genistein and its conjugated metabolites. Toxicol Sci 78(S-1):119 [Abstract 579].

Kremer J, Clewell RA, **Borghoff SJ**. 2004. Physiologically based pharmacokinetic (PBPK) modeling of di-n-butyl phthalate (DBP) in pregnant rats. Toxicol Sci 78(S-1):417.

Schlosser PM, **Borghoff SJ**, Coldham NG, Tran HT, Zager MG. 2004. Mathematical modeling of fast and slow genistein pharmacokinetics (PK) in rats. Toxicol Sci 78(S-1):418 [Abstract 2031].

Borghoff S, Parkinson HD, Ross SM, Gaido K, Sochaski M. Potential activation of human estrogen receptors in HepG2 cells by genistein, genistein-glucuronide and genistein-sulfate, Annual Science Meeting of the Long-Range Research Initiative, American Chemistry Council, Miami, FL, May 2004.

Upmeier A, Elswick BA, Parkinson HD, Krol WL, **Borghoff SJ**. 2003. Pharmacokinetics of genistein following intravenous and oral administration to adult female Sprague-Dawley rats. Toxicol Sci [Abstract no. 709].

Borghoff S, Williams CC, Parkinson HD, Upmeier A. 2003. Transplacental transfer of genistein and conjugated metabolites in Sprague-Dawley Rats. Toxicol Sci [Abstract no. 710].

Schlosser PM, **Borghoff SJ**, Coldham NG, Tran HT, Upmeier A, Zager MG. 2003. Physiologically based pharmacokinetic (PBPK) modeling of genistein in rats. Toxicol Sci [Abstract no. 876].